Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides

Antisense oligonucleotides (ASOs) containing bridged nucleic acids (BNAs) have been proven to be very powerful. However, ensuring a reliable discovery and translational development scheme for this class of ASOs with wider therapeutic windows remains a fundamental challenge. We here demonstrate the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Fumito, Yamamoto, Tsuyoshi, Kobayashi, Tadayuki, Tachibana, Keisuke, Ito, Kosuke Ramon, Hamasaki, Mayumi, Kayaba, Yukina, Terada, Chisato, Yamayoshi, Asako, Obika, Satoshi, Harada-Shiba, Mariko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560717/
https://www.ncbi.nlm.nih.gov/pubmed/34760338
http://dx.doi.org/10.1016/j.omtn.2021.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560717/
https://www.ncbi.nlm.nih.gov/pubmed/34760338
http://dx.doi.org/10.1016/j.omtn.2021.10.008

Ejemplares similares